Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective Observational Study to Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe' in Patients With Essential Hypertension and Primary Hypercholesterolemia.

NCT07685054 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07685054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective Observational Study to Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe' in Patients With Essential Hypertension and Primary Hypercholesterolemia.
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Observational
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 15, 2029
Enrollment
12,700 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension, primary hypercholesterolemia